Mối liên quan giữa hình ảnh PET/CT với đột biến gen KRAS, NRAS, BRAF trong ung thư đại trực tràng

To evaluate the association between SUV, MTV, TLG with KRAS, NRAS and BRAF gene mutations in colorectal cancer. A descriptive, retrospective, and prospective study on 115 colorectal cancer patients who were taken with 18FDG-PET/CT before treatment. Result: The indexes SUVmax at primary tumor, T/NT, T-NT in the group with at least 1 KRAS/NRAS/BRAF gene mutation were higher than in the group without the mutation, (p=0.001, 0.003 and 0.001, respectively). With a threshold value of 9.5 SUVmax could predict KRAS/NRAS/BRAF mutation status with sensitivity of 87.50% and specificity of 41.18%; with a threshold value of 4.72, the T/NT index could predict KRAS/NRAS/BRAF mutation status with a sensitivity of 53.13% and a specificity of 72.55%; with a cutoff value of 6.82 T-NT could predict KRAS/NRAS/BRAF mutation status with a sensitivity of 85.94% and a specificity of 41.18%. SUVmax value at primary tumor in the group with KRAS gene mutation was higher than that in the group without KRAS gene mutation, the difference was statistically significant with p=0.031; The area under the ROC curve was 0.662. With a threshold value of 13.96 SUVmax could predict KRAS mutation status with a sensitivity of 67.35% and a specificity of 61.54%. There is a relationship between SUVmax at primary tumor, T/NT, T-NT and KRAS/NRAS/BRAF gene mutations. There is a relationship between SUVmax at primary tumor and KRAS gene mutation.